Orca-Q pill to help during stem cell transplant
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 1 trial studies Orca-Q to see if it is safe and works when added around the time of an allogeneic (donor) stem cell transplant for certain blood cancers. If you qualify, the study may offer a new option for managing the transplant immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 78 years old (age range depends on donor match and transplant type).
- You have a blood cancer like acute myeloid leukemia (AML), acute lymphoblastic leukemia, mixed-phenotype leukemia, or high-risk/very high-risk myelodysplastic syndrome (MDS).
- You are planning an allogeneic donor stem cell transplant (alloHCT), using an 8/8 or 7/8 donor match or a half-matched (haploidentical) relative donor.
- Your kidneys and heart and lungs meet study thresholds (based on blood tests and breathing/heart measurements).
- You have no prior donor stem cell transplant and no major plans that change the immune treatment plan (like donor lymphocyte infusion or T-cell–depleting medicine).
- You do not have certain infections, viral blood test results (HIV/HTLV/hepatitis B or C), pregnancy/breastfeeding, or uncontrolled autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy, orca-t, given after a lower-intensity chemo and radiation regimen for people with acute myeloid leukemia, mixed phenotype leukemia, or myelodysplastic syndrome. It aims to help patients who cannot tolerate full-intensity transplant conditioning.
This program gives patients with advanced blood cancers access to Orca-T, a special cell therapy, when their prepared dose couldn't be used for routine reasons. It's a way to receive treatment that might otherwise be discarded, as long as their doctor confirms it's safe and appropriate.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests adding a drug called emapalumab to standard medications (cyclophosphamide, tacrolimus, mycophenolate mofetil) to prevent graft-versus-host disease in adults receiving a donor stem cell transplant. This approach aims to reduce complications after transplant.
This trial tests a new way to prepare donor stem cells before a transplant for children and young adults with blood cancers. The goal is to make the transplant safer and more effective, potentially reducing complications like graft-versus-host disease.
This trial tests a new approach for people with advanced blood cancers who are getting a donor stem cell transplant. It aims to improve outcomes by using your own regulatory T cells along with the donor cells.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.